# Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple Dosing

> **NCT03776500** · PHASE1 · COMPLETED · sponsor: **Innovative Medicines for Tuberculosis** · enrollment: 32 (actual)

## Conditions studied

- Tuberculosis, Pulmonary

## Interventions

- **DRUG:** PBTZ169
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03776500
- **Lead sponsor:** Innovative Medicines for Tuberculosis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-21
- **Primary completion:** 2020-03-20
- **Final completion:** 2020-03-20
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03776500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03776500, "Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple Dosing". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03776500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*